First approval in sight for Novartis' CAR-T therapy after panel vote

Nat Biotechnol. 2017 Aug 8;35(8):691-693. doi: 10.1038/nbt0817-691.
No abstract available

MeSH terms

  • Antigens, CD19 / immunology*
  • Drug Approval
  • Humans
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy*
  • Receptors, Antigen, T-Cell / immunology*
  • Receptors, Antigen, T-Cell / therapeutic use
  • United States
  • United States Food and Drug Administration

Substances

  • Antigens, CD19
  • Receptors, Antigen, T-Cell
  • tisagenlecleucel